The purpose of this study is to see if etentamig is safe and to identify the optimal etentamig dose when combined with daratumumab in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for transplant.

Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

The purpose of this study is to see at what doses of etentamig combined with Iberdomide is better tolerated and safe for patients with relapsed/refractory multiple myeloma.

The standard treatment for newly-diagnosed multiple myeloma (NDMM) is autologous stem cell transplantation (ASCT). For this procedure, a patient's own healthy, blood-forming cells are collected. The patient then receives high-dose chemotherapy or radiation to kill the cancer cells. Then their healthy cells are returned to their body to recover. While ASCT is effective for many patients, it has significant side effects and may not be the best option for every patient with NDMM. In this research study, participants will receive one of two (2) study treatments: a new regimen of elranatamab plus daratumumab or a conventional regimen of ASCT plus lenalidomide and daratumumab. The delayed use of ASCT, as explored in this research study, is experimental and not standard-of-care.

We are conducting a study to see how money concerns can affect people with advanced cancer. The goal of this study is to see if monthly check-ins about money problems help ease financial worries for adults with advanced cancer who are getting treatment. If you or someone you know is dealing with money stress while having cancer, we'd like to hear from you. Your participation can help improve care for future patients.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and tolerability of giving a new drug called ABBV-453 alone and in combination with other antimyeloma drugs to patients with relapsed or refractory multiple myeloma.

Do you speak Spanish or identify as Hispanic or Latino and have cancer? You can help improve cancer care by sharing your experience. We need patients to complete a one-time survey about your health, background, and cancer treatment. Your input is important and can help others receive better care. Participation involves only a one-time survey, with no required medical tests. ¿Es usted un adulto hispano, latino o de habla hispana con cáncer? Puede ayudar a mejorar la atención del cáncer al compartir su experiencia. Le pedimos a los pacientes que completen una encuesta una sola vez sobre su salud, antecedentes y atención médica durante o después del tratamiento. Su voz es importante y puede ayudar a que otros reciban mejor atención. La participación consiste únicamente en una encuesta, sin pruebas médicas obligatorias.

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

By doing this study, we hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to persons with multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.

Do you have multiple myeloma (MM)? Has your MM returned after responding to initial treatment (relapsed) or is not responding to treatment (refractory)? If so, you may be able to participate in this cell therapy research study to learn more about using modified immune cells as possible treatment.